Russian Hill Pharmaceuticals

Building on NIH research, we are developing a patent pending pharmaceutical for treatment of pain, without the risks seen with opioids or NSAIDs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded October 2019
  • Employees 2
  • Incorporation Type Not Incorporated
  • Website http://In development

Company Summary

Building on work done by Li Zhang at the NIH, we have invented a compound that targets the a3 glycine receptor in the spine with total selectivity.

Using patch clamp analysis, we have demonstrated that this compound activates the a3 glycine receptor to strongly block transmission of pain signals to the brain.

We are developing this compound as an effective substitute for opioids and NSAIDs in treatment of chronic and inflammatory pain.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free